WO2008122100A1 - Composition for supporting restful sleep comprising valerian root extract and methylcobalamim - Google Patents
Composition for supporting restful sleep comprising valerian root extract and methylcobalamim Download PDFInfo
- Publication number
- WO2008122100A1 WO2008122100A1 PCT/CA2007/000576 CA2007000576W WO2008122100A1 WO 2008122100 A1 WO2008122100 A1 WO 2008122100A1 CA 2007000576 W CA2007000576 W CA 2007000576W WO 2008122100 A1 WO2008122100 A1 WO 2008122100A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- sleep
- extract
- valerian root
- methylcobalamin
- Prior art date
Links
- 230000007958 sleep Effects 0.000 title claims abstract description 44
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 229940038779 valerian root extract Drugs 0.000 title abstract description 6
- 239000001192 valeriana officinalis l. rhizome/root Substances 0.000 title abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 15
- 235000007672 methylcobalamin Nutrition 0.000 claims abstract description 15
- 239000011585 methylcobalamin Substances 0.000 claims abstract description 15
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 claims abstract description 15
- 230000001737 promoting effect Effects 0.000 claims abstract description 5
- 244000126014 Valeriana officinalis Species 0.000 claims description 20
- 235000013832 Valeriana officinalis Nutrition 0.000 claims description 20
- 235000016788 valerian Nutrition 0.000 claims description 20
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims description 11
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims description 11
- 229960003987 melatonin Drugs 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 9
- 206010039897 Sedation Diseases 0.000 claims description 7
- 230000036280 sedation Effects 0.000 claims description 7
- 102000005915 GABA Receptors Human genes 0.000 claims description 6
- 108010005551 GABA Receptors Proteins 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 239000007909 solid dosage form Substances 0.000 claims description 5
- 230000033764 rhythmic process Effects 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 8
- 235000015872 dietary supplement Nutrition 0.000 description 7
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 6
- 229940045999 vitamin b 12 Drugs 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 4
- 230000027288 circadian rhythm Effects 0.000 description 4
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 208000010340 Sleep Deprivation Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 230000000949 anxiolytic effect Effects 0.000 description 3
- 210000000133 brain stem Anatomy 0.000 description 3
- 239000007894 caplet Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000000153 supplemental effect Effects 0.000 description 3
- FEBNTWHYQKGEIQ-SUKRRCERSA-N valerenic acid Chemical compound C[C@@H]1CC[C@@H](\C=C(/C)C(O)=O)C2=C(C)CC[C@H]12 FEBNTWHYQKGEIQ-SUKRRCERSA-N 0.000 description 3
- FUHPCDQQVWLRRY-UHFFFAOYSA-N valerenic acid Natural products CC1CCC(C=C(/C)C(=O)O)C2C1CC=C2C FUHPCDQQVWLRRY-UHFFFAOYSA-N 0.000 description 3
- 241001535291 Analges Species 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000003371 gabaergic effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000010197 meta-analysis Methods 0.000 description 2
- ZJQHPWUVQPJPQT-UHFFFAOYSA-N muscimol Chemical compound NCC1=CC(=O)NO1 ZJQHPWUVQPJPQT-UHFFFAOYSA-N 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 239000003148 4 aminobutyric acid receptor blocking agent Substances 0.000 description 1
- 102000011848 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase Human genes 0.000 description 1
- 108010075604 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010016352 Feeling of relaxation Diseases 0.000 description 1
- 229940098788 GABA receptor antagonist Drugs 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000006279 cobamamide Nutrition 0.000 description 1
- 239000011789 cobamamide Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000020650 eye health related herbal supplements Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000003391 methylcobalamin group Chemical group 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007372 neural signaling Effects 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000015355 regulation of circadian sleep/wake cycle, sleep Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 230000008454 sleep-wake cycle Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 235000020767 valerian extract Nutrition 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/84—Valerianaceae (Valerian family), e.g. valerian
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- Composition for supporting restful sleep comprising Valerian root extract and Methylcobalamm
- the present invention relates to supplemental compositions and methods for promoting and supporting restful sleep in an individual via the induction of sedation and melatonin support.
- insomnia is estimated to affect a significant portion of North Americans per year and is associated with health problems and economic loss (Stoller MK. Economic effects of insomnia. Clin Ther. 1994 Sep- Oct;16(5):873-97 Abstract).
- Sleep as well as the control of sleep are complex processes involving multiple neuro-chemical pathways and associated brain structures. It is a shift in the balance of distinct physiological changes, involving bothe distinct physiological changes and involves both positive and negative neural signaling.
- the regulation of sleep in humans is governed by three processes - each influenced by hormonal and environmental factors: a daily sleep-wake cycle influenced by a circadian rhythm (24 hour cycle) tied to light-dark cycles.
- Strategies to improve sleep are beneficial, not only in terms of physical health, but also in terms of emotional health. Furthermore, reinforcement of sleep of adequate quantity and quality positively impacts most aspect of daily life. Summary of the Invention
- the present invention is directed towards a composition for supporting a restful period of sleep via the induction of sedation and providing anxiolytic compounds comprising Valerian root extract and Methylcobalamin.
- a method for same also provided comprising the step of the administration to an individual a composition comprising an extract of Valerian root supplying valerinic acid and Methlycobalamin.
- improvements in sleep may be both of a quantitative nature e.g. increased length of sleep, decreased time of sleep onset, and of a qualitative nature e.g. deeper, more restful undisturbed. It is further understood that improvements in sleep may also be both direct and indirect. For example, sleep will be directly improved by the administration of a substance which is known to reduce time to sleep onset. Sleep may be indirectly improved, for example, by the administration of a substance which is known to result in feelings of relaxation and calmness. Valerian Root Extract
- Valerian (Valeriana officinalis) is a perennial plant native to North
- GABA Gamma Aminobutyric Acid
- the neurotransmitter GABA is the primary inhibitory neurotransmitter of the Central
- Nervous system One of its effects is to induce sleep. Signaling through the GABA- receptor changes the electrochemical gradient of a given neuron, leading to inhibition of its activity.
- Benzodiazepines are thought to act via interaction with the GABA receptor; enhancing the inhibitory effects of GABA. As such, benzodiazepines are a widely used class of drugs primarily used as tranquilizers, muscle-relaxants, hypnotics or sedatives. It is believed that active constituents of Valerian produce sleep- enhancing sedative effects through this mechanism (Hadley S, Petry JJ. Valerian. Am
- Valerinic acid specifically has been shown to decrease neural activity in the brainstem produced by the GABA receptor antagonist, muscimol.
- GABA(A) receptor function Yuan CS, Mehendale S, Xiao Y, Aung HH, Xie JT, Ang-Lee MK.
- GABA(A) receptor function Yuan CS, Mehendale S, Xiao Y, Aung HH, Xie JT, Ang-Lee MK.
- the gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity Anesth Analg. 2004 Feb;98(2):353-8).
- the composition includes an extract of Valerian root having valerinic acid as an active component to promote a sedation leading to sleep through a GABAergic-dependant mechanism.
- a serving of the supplemental composition includes from about 0.001 g to about 1.000 g of an extract of Valerian root.
- the preferred dosage of an extract of Valerian root in the present invention comprises about 0.100 g per serving.
- Vitamin Bl 2 (Methylcobalamin)
- Vitamin B 12 is a water-soluble cofactor for the enzyme methionine synthase, which transfers methyl groups. There are two forms of Vitamin B 12 - Adenosylcobalamin which is usually present in tissue and Methylcobalamin which is usually present in plasma. Vitamin B 12 plays an important role in many important biological processes (Volkov I, Press Y, Rudoy I. Vitamin B12 could be a "master key" in the regulation of multiple pathological processes. J Nippon Med Sch. 2006 Apr;73(2):65-9).
- Methylcobalamin As noted above, plays a role in melatonin production.
- the composition includes Methylcobalamin to promote quality sleep by supporting the endogenous function of melatonin.
- a serving of the supplemental composition includes from about 0.000001 g to about 0.00001 g of Methylcobalamin.
- the preferred dosage of Methylcobalamin in the present invention comprises about 0.000006 g per serving.
- the composition comprises an extract of Valerian root and Methylcobalamin for the support of a restful period of sleep in an individual via the induction of sedation and melatonin support to maintain circadian rhythms relative to local time of a 24-hour day.
- composition of the present invention may be provided in various embodiments, however, the nutritional supplement resultant therefrom said embodiements may be administered to an individual in acceptable any form.
- the dosage form of the nutritional supplement may be provided as, e.g., a powder beverage mix, a liquid beverage, a ready-to-eat bar or drink product, a capsule, a liquid capsule, a tablet, a caplet, a soft-gel capsule or as a dietary gel.
- the preferred dosage forms of the present invention are as a tablet or caplet.
- the composition may be provided in a solid dosage form having specific controlled release characteristics.
- the composition may be provided in a layered solid dosage form.
- each individual layer will provide unique dissolution characteristics. In this way a controlled release of the composition can be achieved.
- each layer contains a homogeneous mixture of ingredients whereby the release of all ingredients is dependent upon the characteristics of each given layer.
- each layer contains a distinct set of specific ingredients which differ according to the layers such that different specific ingredients are released from the solid dosage form at different times according to a predetermined schedule. In all aspects of this embodiment, a temporally controlled release of ingredients is achieved.
- the dosage form of the nutritional supplement may be provided in accordance with customary processing techniques for herbal and nutritional supplements in any of the forms mentioned above. Additionally, the nutritional supplement set forth in the example embodiment herein may contain any appropriate number and type of excipients, as is well known in the art.
- present nutritional composition or those similarly envisioned by one of skill in the art may be utilized in methods to promote and support a restful period of sleep in an individual.
- the present composition may be used not only as a sole means of promoting and supporting restful sleep but may also be used either in addition to other similarly-directed compositions or as a component of a larger composition. Furthermore, as a component of a greater composition the present invention, may serve to provide a given aspect contributing to the function of broader composition wherein other requirements for good sleep in an individual are addressed by additional compositions.
- a method for improving the onset of sleep and improvement of sleep quality comprises at least the step of administering to an individual a therapeutically acceptable amount of the composition of the present invention.
- a nutritional supplement to help promote and support restful, quality sleep for use immediately prior to bedtime contains the following:
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Anesthesiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A method for promoting and supporting restful, quality sleep in an individual comprising the administration of a composition comprising Valerian root extract and Methylcobalamin.
Description
Composition for supporting restful sleep comprising Valerian root extract and Methylcobalamm
Field of the Invention
[001] The present invention relates to supplemental compositions and methods for promoting and supporting restful sleep in an individual via the induction of sedation and melatonin support.
Background of the Invention
[002] Sleep occupies about one-third of our life and is necessary for mental and physical well-being. It additionally affects mood, behavior and physiology. The need for sleep is a biological drive similar to thirst or hunger. Interestingly though, the function of sleep is largely unknown, however some evidence indicates that sleep is required for learning. It is clear that the impairment of sleep is detrimental to one's health, hi humans, similarly, mild sleep deprivation also results in indications of impaired immune system function (Irwin M, McClintick J, Costlow C, Former M, White J, Gillin JC. Partial night sleep deprivation reduces natural killer and cellular immune responses in humans. FASEB J. 1996 Apr;10(5):643-53.). Prolonged sleep deprivation is even known to result in death. It has been determined my many that an individual can survive longer without food than one can without sleep; thus indicating the importance of sleep. Additionally, insomnia is estimated to affect a significant portion of North Americans per year and is associated with health problems and economic loss (Stoller MK. Economic effects of insomnia. Clin Ther. 1994 Sep- Oct;16(5):873-97 Abstract).
[003] Sleep as well as the control of sleep are complex processes involving multiple neuro-chemical pathways and associated brain structures. It is a shift in the balance of distinct physiological changes, involving bothe distinct physiological changes and involves both positive and negative neural signaling.. The regulation of sleep in humans is governed by three processes - each influenced by hormonal and environmental factors: a daily sleep-wake cycle influenced by a circadian rhythm (24 hour cycle) tied to light-dark cycles. [004] Strategies to improve sleep are beneficial, not only in terms of physical health, but also in terms of emotional health. Furthermore, reinforcement of sleep of adequate quantity and quality positively impacts most aspect of daily life.
Summary of the Invention
[005] The foregoing needs and other needs and objectives that will become apparent for the following description are achieved in the present invention, which comprises Valerian root extract and Methylcobalamin for the support of restful sleep in an individual via the induction of sedation and providing anxiolytic compounds and melatonin support.
Detailed Description of the Invention
[006] In the following description, for the purposes of explanations, numerous specific details are set forth in order to provide a thorough understanding of the present invention. It will be apparent, however, to one of ordinary skill in the art that the present invention may be practiced without these specific details.
[007] The present invention is directed towards a composition for supporting a restful period of sleep via the induction of sedation and providing anxiolytic compounds comprising Valerian root extract and Methylcobalamin. A method for same also provided comprising the step of the administration to an individual a composition comprising an extract of Valerian root supplying valerinic acid and Methlycobalamin.
[008] Incorporated herein by reference are the specifications of co-pending applications (filed contemporaneously with the present application) entitled "Composition for a Feeling of Relaxation" and "Composition for a Feeling of Calmness".
[009] It is herein understood that improvements in sleep may be both of a quantitative nature e.g. increased length of sleep, decreased time of sleep onset, and of a qualitative nature e.g. deeper, more restful undisturbed. It is further understood that improvements in sleep may also be both direct and indirect. For example, sleep will be directly improved by the administration of a substance which is known to reduce time to sleep onset. Sleep may be indirectly improved, for example, by the administration of a substance which is known to result in feelings of relaxation and calmness.
Valerian Root Extract
[0010] Valerian (Valeriana officinalis) is a perennial plant native to North
America, Asia and Europe. The root has been traditionally used as treatment for anxiety and insomnia. A meta-analysis of available studies suggest that Valerian root extract may improve sleep absent of side-effects (Bent S, Padula A, Moore D, Patterson M, Mehling W. Valerian for sleep: a systematic review and meta-analysis. Am J Med. 2006 Dec;119(12):1005-12 Abstract) acting particularly to decrease the time to sleep onset and improved sleep quality in individuals.
[0011] Valerian has been shown to modulate Gamma Aminobutyric Acid (GABA) receptors (Yuan CS, Mehendale S, Xiao Y, Aung HH, Xie JT, Ang-Lee MK.
The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity. Anesth Analg. 2004 Feb;98(2):353-8). The neurotransmitter GABA, is the primary inhibitory neurotransmitter of the Central
Nervous system. One of its effects is to induce sleep. Signaling through the GABA- receptor changes the electrochemical gradient of a given neuron, leading to inhibition of its activity. Benzodiazepines are thought to act via interaction with the GABA receptor; enhancing the inhibitory effects of GABA. As such, benzodiazepines are a widely used class of drugs primarily used as tranquilizers, muscle-relaxants, hypnotics or sedatives. It is believed that active constituents of Valerian produce sleep- enhancing sedative effects through this mechanism (Hadley S, Petry JJ. Valerian. Am
Fam Physician. 2003 Apr 15;67(8): 1755-8).
[0012] Valerinic acid specifically has been shown to decrease neural activity in the brainstem produced by the GABA receptor antagonist, muscimol. Data from this study suggests that the pharmacological effects of valerian extract and valerenic acid are mediated through modulation of GABA(A) receptor function (Yuan CS, Mehendale S, Xiao Y, Aung HH, Xie JT, Ang-Lee MK. The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity. Anesth Analg. 2004 Feb;98(2):353-8).
[0013] In a preferred embodiment of the present invention which is set forth in greater detail in the example below, the composition includes an extract of Valerian root having valerinic acid as an active component to promote a sedation leading to sleep through a GABAergic-dependant mechanism. A serving of the supplemental
composition includes from about 0.001 g to about 1.000 g of an extract of Valerian root. The preferred dosage of an extract of Valerian root in the present invention comprises about 0.100 g per serving.
Vitamin Bl 2 (Methylcobalamin) [0014] Vitamin B 12 is a water-soluble cofactor for the enzyme methionine synthase, which transfers methyl groups. There are two forms of Vitamin B 12 - Adenosylcobalamin which is usually present in tissue and Methylcobalamin which is usually present in plasma. Vitamin B 12 plays an important role in many important biological processes (Volkov I, Press Y, Rudoy I. Vitamin B12 could be a "master key" in the regulation of multiple pathological processes. J Nippon Med Sch. 2006 Apr;73(2):65-9).
[0015] One specific area of vitamin B 12 research pertains to the treatment of sleep disturbances. The Methylcobalamin form of vitamin B 12 has been shown to be associated with increases in the quality of sleep and feelings of post-sleep restfulness (Mayer G, Kroger M, Meier-Ewert K. Effects of vitamin B 12 on performance and circadian rhythm in normal subjects. Neuropsychopharmacology. 1996 Nov;15(5):456-64). The mode of action of the benefit of vitamin B12 to sleep may be via support of melatonin synthesis (Methylcobalamin. Altern Med Rev. 1998 Dec;3(6):461-3). [0016] Methylcobalamin, as noted above, plays a role in melatonin production. Melatonin is the hormone responsible for the proper cycling of normal diurnal rhythms, or the circadian rhythm. As people get older, the body is less efficient at making this hormone. B 12 supplementation has been shown to help some older adults sleep better, most likely through an increase in melatonin production. [0017] In a preferred embodiment of the present invention which is set forth in greater detail in the example below, the composition includes Methylcobalamin to promote quality sleep by supporting the endogenous function of melatonin. A serving of the supplemental composition includes from about 0.000001 g to about 0.00001 g of Methylcobalamin. The preferred dosage of Methylcobalamin in the present invention comprises about 0.000006 g per serving.
[0018] In a preferred embodiment of the present invention, the composition comprises an extract of Valerian root and Methylcobalamin for the support of a restful
period of sleep in an individual via the induction of sedation and melatonin support to maintain circadian rhythms relative to local time of a 24-hour day.
[0019] Not wishing to be bound by theory, it is believed that the components of the present invention will act in concert through distinct mechanisms to promote and support a restful period of sleep. The extract of Valerian root will act to promote sleep through the modulation GABA-receptors providing sedative and anxiolytic effect through GABA receptor agonism, while Methylcobalaniin will act to support the normal endogenous activity of melatonin to regulate sleep according to a 24-hours system. [0020] The composition of the present invention may be provided in various embodiments, however, the nutritional supplement resultant therefrom said embodiements may be administered to an individual in acceptable any form. For instance, the dosage form of the nutritional supplement may be provided as, e.g., a powder beverage mix, a liquid beverage, a ready-to-eat bar or drink product, a capsule, a liquid capsule, a tablet, a caplet, a soft-gel capsule or as a dietary gel. The preferred dosage forms of the present invention are as a tablet or caplet.
[0021] An embodiment of the present invention the composition may be provided in a solid dosage form having specific controlled release characteristics. Advantageously, the composition may be provided in a layered solid dosage form. In such a form, each individual layer will provide unique dissolution characteristics. In this way a controlled release of the composition can be achieved. In one aspect of this embodiment, each layer contains a homogeneous mixture of ingredients whereby the release of all ingredients is dependent upon the characteristics of each given layer. In an alternative aspect of this embodiment, each layer contains a distinct set of specific ingredients which differ according to the layers such that different specific ingredients are released from the solid dosage form at different times according to a predetermined schedule. In all aspects of this embodiment, a temporally controlled release of ingredients is achieved.
[0022] Furthermore, the dosage form of the nutritional supplement may be provided in accordance with customary processing techniques for herbal and nutritional supplements in any of the forms mentioned above. Additionally, the
nutritional supplement set forth in the example embodiment herein may contain any appropriate number and type of excipients, as is well known in the art.
[0023] The present nutritional composition or those similarly envisioned by one of skill in the art may be utilized in methods to promote and support a restful period of sleep in an individual.
[0024] Advantageously, the present composition may be used not only as a sole means of promoting and supporting restful sleep but may also be used either in addition to other similarly-directed compositions or as a component of a larger composition. Furthermore, as a component of a greater composition the present invention, may serve to provide a given aspect contributing to the function of broader composition wherein other requirements for good sleep in an individual are addressed by additional compositions.
[0025] Additionally, by way of ingestion of the composition of the present invention, a method for improving the onset of sleep and improvement of sleep quality is provided. The method of the present invention comprises at least the step of administering to an individual a therapeutically acceptable amount of the composition of the present invention.
[0026] Although the following example illustrates the practice of the present invention in one of its example compositional embodiments, the example should not be construed as limiting the scope of the invention. Other embodiments will be apparent to one of skill in the art from consideration of the specifications and example.
Example
[0027] A nutritional supplement to help promote and support restful, quality sleep for use immediately prior to bedtime. A serving of the nutritional supplement as a caplet contains the following:
[0028] About 0.1000 g of an extract of Valerian root standardized to Valerinic acid and about 0.000006 g of Methycobalamin.
Extensions and Alternatives [0029] In the foregoing specification, the invention has been described with a specific embodiment thereof, however, it will be evident that various modifications
and changes may be made thereto without departing from the broader spirit and scope of the invention.
Claims
1. A composition comprising an effective amount of an extract of Valerian root and an effective amount Methylcobalamin for promoting sleep in a mammal.
2. The composition of claim 1 wherein the extract of Valerian root agonizes GABA-receptors to induce sedation in a mammal.
3. The composition of claim 1 wherein the extract of Valerian root is standardized to Valerinic Acid.
4. The composition of claim 1 wherein the Methylcobalamin supports the endogenous function of melatonin to maintain normal diurnal rhythms according to a
24-hour cycle.
5. A method of promoting sleep in an individual, the method comprising the step of administering to a mammal a therapeutically effect amount of a composition comprising an extract of Valerian root and Methylcobalamin.
6. The method of claim 5 wherein the extract of Valerian root agonizes GABA- receptors to induce sedation in a mammal.
7. The method of claim 6 wherein the extract of Valerian root is standardized to Valerinic Acid.
8. The method of claim 5 wherein the Methylcobalamin supports the endogenous function of melatonin to maintain normal diurnal rhythms according to a 24-hour cycle.
9. The composition of claim 1, wherein the composition is provided in a layered release solid dosage form.
10. The method of claim 5, wherein the composition is provided in a layered release solid dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CA2007/000576 WO2008122100A1 (en) | 2007-04-05 | 2007-04-05 | Composition for supporting restful sleep comprising valerian root extract and methylcobalamim |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CA2007/000576 WO2008122100A1 (en) | 2007-04-05 | 2007-04-05 | Composition for supporting restful sleep comprising valerian root extract and methylcobalamim |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2008122100A1 true WO2008122100A1 (en) | 2008-10-16 |
Family
ID=39830425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CA2007/000576 WO2008122100A1 (en) | 2007-04-05 | 2007-04-05 | Composition for supporting restful sleep comprising valerian root extract and methylcobalamim |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2008122100A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150150853A1 (en) * | 2012-02-07 | 2015-06-04 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Promoting sleep using at1 receptor blockers |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6869622B2 (en) * | 1999-07-21 | 2005-03-22 | Ancile Pharmaceuticals, Inc. | Composition for improving sleep quality and efficiency, and methods of preparing and using the composition |
| US20060246129A1 (en) * | 2005-04-29 | 2006-11-02 | Linardakis Nikos M | Composition for use in treatment of sleep problems and method for same |
-
2007
- 2007-04-05 WO PCT/CA2007/000576 patent/WO2008122100A1/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6869622B2 (en) * | 1999-07-21 | 2005-03-22 | Ancile Pharmaceuticals, Inc. | Composition for improving sleep quality and efficiency, and methods of preparing and using the composition |
| US20060246129A1 (en) * | 2005-04-29 | 2006-11-02 | Linardakis Nikos M | Composition for use in treatment of sleep problems and method for same |
Non-Patent Citations (4)
| Title |
|---|
| BALDERER G. AND BORBELY A.: "Effects of valerian on human sleep", PSYCHOPHARMACOLOGY (BERLIN), vol. 87, 1985, pages 406 - 409 * |
| COXETER P.D. ET AL.: "Valerian does not appear to reduce symptoms for patients with chronic insomnia in general practice using a series of randomised n-of-1 trials", COMPLEMENTARY THERAPIES IN MEDICINE, vol. 11, 2003, pages 215 - 222 * |
| OHTA T. ET AL.: "Treatment of persistent sleep-wake schedule disorders in adolescents with methylcobalamin (vitamin B12)", SLEEP, vol. 14, 1991, pages 414 * |
| SHINOMIYA K. ET AL.: "Effects of valerian extract on the sleep wake cycle in sleep disturbed rats", ACTA MEDICA OKAYAMA, vol. 59, 2005, pages 89 - 92 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150150853A1 (en) * | 2012-02-07 | 2015-06-04 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Promoting sleep using at1 receptor blockers |
| US10813915B2 (en) * | 2012-02-07 | 2020-10-27 | University of Pittsburgh—of the Commonwealth System of Higher Education | Promoting sleep using AT1 receptor blockers |
| US11439624B2 (en) | 2012-02-07 | 2022-09-13 | University of Pittsburgh—of the Commonwealth System of Higher Education | Promoting sleep using AT1 receptor blockers |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Peuhkuri et al. | Diet promotes sleep duration and quality | |
| Imbalance | Nutrients and botanicals for treatment of stress: adrenal fatigue, neurotransmitter imbalance, anxiety, and restless sleep | |
| Singh | Nutrient and stress management | |
| Hinton et al. | GABA-enriched teas as neuro-nutraceuticals | |
| US20080248106A1 (en) | Melatonin-based composition for improved sleep | |
| US20080254121A1 (en) | Multi-layer melatonin composition | |
| US9375463B2 (en) | Compositions and methods for improving sleep using a nutraceutical formulation | |
| WO2014175773A1 (en) | A formula for restoring normal sleep and biological rhythms | |
| Gulati et al. | Nutraceuticals as adaptogens: their role in health and disease | |
| US20150147306A1 (en) | Composition for treating a circadian rhythm disorder | |
| CN109198353A (en) | A kind of analgesic sedative solid beverage and preparation method thereof | |
| WO2008122100A1 (en) | Composition for supporting restful sleep comprising valerian root extract and methylcobalamim | |
| US20080248140A1 (en) | Composition for supporting restful sleep | |
| Potter et al. | Alternative treatments in pediatric bipolar disorder | |
| da Silva et al. | Effects of the single supplementation and multiple doses of Passiflora incarnata L. on human anxiety: A clinical trial, double-blind, placebo-controlled, randomized | |
| Wu et al. | Effects and mechanisms of a new multivitamin on chronic metabolic syndromes and aging | |
| US20080248141A1 (en) | Composition for a feeling of relaxation | |
| Lakhan et al. | Nutritional supplements and sleep: an overview | |
| Babilas | Nutritional diseases | |
| Dal Lin et al. | Integrated approach to hypertension | |
| US7374785B1 (en) | Composition for a feeling of calmness | |
| US20210299097A1 (en) | Compositions for a dietary supplement to improve sleep | |
| Weeks et al. | Physiological and Cellular Targets of Neurotrophic Anxiolytic Phytochemicals in Food and Dietary Supplements | |
| EP2150250A1 (en) | Composition for supressing appetite, improving tone and mood, with a natural antidepressant activity and with an antiasthenic effect | |
| Alshammari et al. | EXPLORING THE LINK BETWEEN DIET AND MENTAL HEALTH: A REVIEW OF RECENT FINDINGS. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07719506 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 07719506 Country of ref document: EP Kind code of ref document: A1 |